With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

Forbes contributors publish independent expert analyses and insights. I cover news on drugs and R&D in the pharma industry via my Well, I was mistaken in that view, as I was told by Ms. Sarah ...

GlaxoSmithKline is set to lay off a small number of R&D employees at its Stevenage, U.K., site as part of a wider rethink of its drug development operation. The layoffs come as GSK revises its R&D ...

GSK multiplies ‘science x technology x culture’ to improve the R&D pipeline Multinational pharmaceutical company GlaxoSmithKline PLC is one of the largest drug developers in the world.

She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with Celgene’s eight at the same stage of development.

Investing in companies that pay above average dividends has historically been a good investment strategy. Of course investors, specifically those looking for income, want more than just a current ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

GSK is a compelling value investment with a strong balance sheet, profitable drug line-up, and focus on vaccines. Click here to read more on GSK stock now.

Drugmaker GlaxoSmithKline plans to invest up to 130 million pounds ($216 million) in Africa over the next five years as it bets on the importance of the continent in driving long-term demand for ...

Britain's life sciences sector plan receives a mixed reception from the pharmaceutical industry. While the strategy aims to boost R&D, industry leaders criticize the lack of resolution on drug pricing ...

GSK delivered a stellar result for 1Q22, with turnover increasing 32% YOY (32% YOY constant exchange rate or CER) to £9.8 billion (10.5% vs. consensus).